Johan Törlén

Om mig
Publikationer
Populärvetenskap och samverkan

Om mig

Anknuten, disputerat vid Karolinska Institutet 2019. Specialistläkare i
hematologi och biträdande överläkare inom medicinska enheten Cellterapi och Allogen
Stamcellstransplantation (CAST) på Karolinska Universitetssjukhuset

Artiklar

Article: TRANSPLANTATION AND CELLULAR THERAPY. 2023;29(6):376.e1-376.e11
Effect of mTOR Inhibition with Sirolimus on Natural Killer Cell Reconstitution in Allogeneic Stem Cell Transplantation
Haroun-Izquierdo A; Lanuza PM; Pfefferle A; Netskar H; Ask EH; Torlen J; Bjorklund A; Sohlberg E; Malmberg K-J
Article: FRONTIERS IN IMMUNOLOGY. 2022;13:954716
T cell receptor excision circles are potential predictors of survival in adult allogeneic hematopoietic stem cell transplantation recipients with acute myeloid leukemia
Soderstrom A; Vonlanthen S; Jonsson-Videsater K; Mielke S; Lindahl H; Torlen J; Uhlin M
Article: ORAL DISEASES. 2021;27(5):1217-1225
Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graft-versus-host disease prophylaxis
Garming Legert K; Ringden O; Remberger M; Torlen J; Mattsson J; Dahllof G
Article: INTERNATIONAL JOURNAL OF HEMATOLOGY. 2021;113(5):712-722
Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care
Ringden O; Remberger M; Torlen J; Finnbogadottir S; Svahn B-M; Sadeghi B
Article: CTS-CLINICAL AND TRANSLATIONAL SCIENCE. 2020;13(2):293-300
Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan-Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation
El-Serafi I; Remberger M; Ringden O; Torlen J; Sundin M; Bjorklund A; Winiarski J; Mattsson J
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(6):1260-1268
Effect of Graft-versus-Host Disease Prophylaxis Regimens on T and B Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation
Torlen J; Gaballa A; Remberger M; Mork L-M; Sundberg B; Mattsson J; Uhlin M
Article: FRONTIERS IN IMMUNOLOGY. 2019;10:189
Individualization of Hematopoietic Stem Cell Transplantation Using Alpha/Beta T-Cell Depletion
Radestad E; Sundin M; Torlen J; Thunberg S; Onfelt B; Ljungman P; Watz E; Mattsson J; Uhlin M
Article: INTERNATIONAL JOURNAL OF HEMATOLOGY. 2017;106(4):471-475
Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation
Remberger M; Torlen J; El Serafi I; Garming-Legert K; Bjorklund A; Ljungman P; Sundin M; Hassan M; Mattsson J
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2017;23(4):677-683
Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based Decisions
Torlen J; Remberger M; Le Blanc K; Ljungman P; Mattsson J
Article: FRONTIERS IN IMMUNOLOGY. 2017;8:717
Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease
Stikvoort A; Chen Y; Radestad E; Torlen J; Lakshmikanth T; Bjorklund A; Mikes J; Achour A; Gertow J; Sundberg B; Remberger M; Sundin M; Mattsson J; Brodin P; Uhlin M
Article: HAEMATOLOGICA. 2016;101(11):1417-1425
A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation
Torlen J; Ringden O; Garming-Legert K; Ljungman P; Winiarski J; Remes K; Itala-Remes M; Remberger M; Mattsson J
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2016;22(9):1684-1689
Risk Factors for Invasive Mold Infections and Implications for Choice of Prophylaxis after Allogeneic Stem Cell Transplantation
Blennow O; Remberger M; Torlen J; Szakos A; Ljungman P; Mattsson J
Article: TRANSPLANT INFECTIOUS DISEASE. 2015;17(6):785-794
Prolonged outbreak of adenovirus A31 in allogeneic stem cell transplant recipients
Swartling L; Allard A; Torlen J; Ljungman P; Mattsson J; Sparrelid E
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2015;21(5):889-893
Effect of Total Nucleated and CD34⁺ Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation
Remberger M; Torlen J; Ringden E; Engstrom M; Watz E; Uhlin M; Mattsson J
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2014;20(9):1418-1425
Low CD34 Dose Is Associated with Poor Survival after Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodygplastic Syndrome
Torlen J; Ringden O; Le Rademacher J; Batiwalla M; Chen J; Erkers T; Ho V; Kebriaei P; Keever-Taylor C; Kindwall-Keller T; Lazarus HM; Laughlin MJ; Lill M; O'Brien T; Perales M-A; Rocha V; Savani BN; Szwajcer D; Valcarcel D; Eapen M
Article: PEDIATRIC TRANSPLANTATION. 2014;18(4):398-404
Home care during neutropenia after allogeneic hematopoietic stem cell transplantation in children and adolescents is safe and may be more advantageous than isolation in hospital
Ringden O; Remberger M; Torlen J; Engstrom M; Fjaertoft G; Mattsson J; Svahn B-M

Alla övriga publikationer

Review: SUPPORTIVE CARE IN CANCER. 2023;31(12):702
Incidence, severity, and temporal development of oral complications in pediatric allogeneic hematopoietic stem cell transplant patients - a multicenter study
Agholme MB; Dahlloef G; Toerlen JK; Majorana A; Brennan MT; von Bueltzingsloewen I; Tan PL; Hu S; Sim YF; Hong C
Editorial comment: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2020;107(2):308
Protocol Changes Lead to Lowering of SOS Rates
Conference publication: BONE MARROW TRANSPLANTATION. 2020;55(SUPPL 1):336
Cytokine Levels following Allogeneic Hematopoietic Stem Cells Transplantation. A match-pair Analysis of Home Care Versus Hospital Care
Ringden O; Remberger M; Torlen J; Finnbogadottir S; Svahn B-M; Sadeghi B
Doctoral thesis: 2019
From risk indices to reconstitution of immunity : studies of outcome-related factors in patients undergoing allogeneic hematopoietic stem cell transplantation
Törlén JK
Conference publication: BONE MARROW TRANSPLANTATION. 2017;52:S338-S339
Toxicological side effects of fludarabin and treosulfan conditioning before allogeneic stem-cell transplantation
Mattsson J; Torlen J; El Serafi I; Legert KG; Bjorklund A; Ljungman P; Sundin M; Hassan M; Remberger M
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):264
Identifying cellular subsets diagnostic for severity chronic GVHD
Stikvoort A; Chen Y; Radestad E; Karlsson-Torlen J; Tadepally L; Bjorklund A; Mikes J; Achour A; Gertow J; Sundberg B; Remberger M; Sundin M; Mattsson J; Brodin P; Uhlin M
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2016;22(3):S415
Identifying Cellular Subsets Diagnostic for Severity and Organ Specific Chronic GVHD
Stikvoort A; Rodestad E; Gertow J; Torlen J; Sundin M; Mattsson J; Uhlin M
Conference publication: BONE MARROW TRANSPLANTATION. 2016;51:S21
A prospective randomized study comparing tacrolimus and sirolimus versus cyclosporine and methotrexate as gvhd prophylaxis in allogeneic hematopoietic stem cell transplantation
Torlen J; Ringden O; Garming-Legert K; Ljungman P; Winiarski J; Remes K; Itala-Remes M; Remberger M; Mattsson J
Conference publication: EUROPEAN JOURNAL OF IMMUNOLOGY. 2016;46:844
Identifying cellular subsets diagnostic for severity and organ specificity chronic GVHD
Stikvoort A; Chen Y; Radestad E; Torlen J; Sundberg B; Sundin M; Mattsson J; Brodin P; Uhlin M
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2015;21(2):S351
An Increasing Severity of Chronic GvHD Is Associated to an Activated and Cytotoxic T Cell Mediated Immune-Phenotype
Stikvoort A; Radestad E; Torlen J; Mattsson J; Uhlin M
Conference publication: BONE MARROW TRANSPLANTATION. 2015;50:S77
Prolonged Outbreak of Adenovirus A31 Among Allogeneic Stem Cell Transplant Recipients
Swartling LP; Allard A; Torlen J; Ljungman P; Mattsson J; Sparrelid E

Om mig

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI